⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLTX News
MoonLake Immunotherapeutics Class A Ordinary Shares
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study
businesswire.com
MLTX
Form 8-K
sec.gov
MLTX
Form 8-K
sec.gov
MLTX
Form 8-K
sec.gov
MLTX
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
globenewswire.com
MLTX
MoonLake Immunotherapeutics Announces Proposed Public Offering
globenewswire.com
MLTX
Form 8-K
sec.gov
MLTX
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
globenewswire.com
MLTX
Form 8-K
sec.gov
MLTX
Form 8-K
sec.gov
MLTX